Youssef Samar Samir, Fahmy Ahmed Mohamed, Omran Moataza Hassan, Mohamed Amr Saad, El Desouki Mohamed Ali, El-Awady Mostafa K
Microbial Biotechnology Department, National Research Center, Cairo 12311, Egypt.
Reproductive Health and Family Planning Department, National Research Center, Cairo, Egypt ; INRS-Institut Armand Frappier, Laval, QC, Canada H7V 1B7.
Biomed Res Int. 2014;2014:196712. doi: 10.1155/2014/196712. Epub 2014 Jun 1.
To assess the efficiency of phosphorothioate antisense oligodeoxynucleotide 1 (S-ODN1) on HCV translation inhibition in PBMC compared to hepatoma cells in vitro for the first time.
The study included 34 treatment naive HCV patients. IRES domain III and IV sequence variations were tested in 45 clones from 9 HCV patients. PBMC of HCV positive patients were subjected to S-ODN in vitro. Concomitantly HepG2 cells infected by the same patient's serum were also treated with S-ODN1 for 24 and 48 hours. Cellular RNA was tested for HCV plus and minus strands by reverse transcription polymerase chain reaction (RT-PCR).
Sequence variations were seen in HCV IRES domain III only while domain IV was conserved among all the tested patient's clones. S-ODN1 successfully inhibited HCV translation in HepG2 cells, while in PBMC inhibition was partial.
HCV IRES domain IV is more conserved than domain IIId in genotype 4 HCV patients. S-ODN against HCV IRES domain IV was not efficient to inhibit HCV translation in PBMC under the study conditions. Further studies testing other S-ODN targeting other HCV IRES domains in PBMC should be done.
首次在体外评估硫代磷酸酯反义寡脱氧核苷酸1(S-ODN1)对PBMC中丙型肝炎病毒(HCV)翻译抑制的效率,并与肝癌细胞进行比较。
该研究纳入了34例未经治疗的HCV患者。对来自9例HCV患者的45个克隆进行了IRES结构域III和IV序列变异检测。HCV阳性患者的PBMC在体外接受S-ODN处理。同时,用同一患者血清感染的HepG2细胞也用S-ODN1处理24小时和48小时。通过逆转录聚合酶链反应(RT-PCR)检测细胞RNA中的HCV正负链。
仅在HCV IRES结构域III中观察到序列变异,而在所有测试患者的克隆中结构域IV是保守的。S-ODN1成功抑制了HepG2细胞中的HCV翻译,而在PBMC中抑制是部分性的。
在4型HCV患者中,HCV IRES结构域IV比结构域III更保守。在本研究条件下,针对HCV IRES结构域IV的S-ODN在PBMC中抑制HCV翻译的效果不佳。应开展进一步研究,测试针对PBMC中其他HCV IRES结构域的其他S-ODN。